Myrtelle Enters Into a Worldwide Exclusive License Agreement With Rescue Hearing To Develop and Commercialize Gene Therapy for the Treatment of Hearing Loss
Myrtelle Inc., a clinical stage gene therapy company focused on developing transformative treatments for rare genetic diseases, today announced that it has entered into a worldwide exclusive licensing agreement with UF Innovate | Accelerate at The Hub alum Rescue Hearing Inc. (RHI) to develop a novel gene therapy for DFNB8 genetic hearing loss.
Zomedica Enters Into Strategic Investment and Potential Collaboration for VetGuardian Monitoring Product Line
Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, announced that it has purchased a $1.0 million convertible note from UF startup Structured Monitoring Products, Inc. (SMP), makers of the VetGuardianTM wireless remote pet monitoring platform, and in connection therewith has acquired the option to act as a sales agent for SMP's platform. Under the terms of the agreement, Zomedica will also have the option to acquire the VetGuardian product line for use in Animal Health.
UF Scientists May Have Found a Way to More Efficiently Apply Genome Editing to Plant Breeding
New research led by a University of Florida scientist shows a development regulator can help plants grow. In the bigger picture, the study’s results also may help genome editing and as a result, plant breeding.
Alcyone Presents Preclinical Data on Gene Therapy Programs With the Center for Gene Therapy at the Abigail Wexner Research Institute (AWRI) at ASGCT 2022
Sid Martin Client Alcyone Therapeutics Inc. ("Alcyone"), a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions, presented preclinical data showing the Company's partnered novel adeno associated virus serotype 9 (AAV9) gene therapy vector ACTX-101 safely and effectively reactivates the inactive X chromosome in a Rett syndrome mouse model and is safe in a preliminary nonhuman primate study at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting.
Exactech Announces FDA Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing System
UF Startup Exactech, a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, announced that the U.S. Food and Drug Administration (FDA) has granted a Breakthrough Device Designation for JointMedica’s Polymotion® Hip Resurfacing System.
AGTC Announces Positive Three-Month Interim Results From Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa
UF startup and UF Innovate | Sid Martin Biotech graduate Applied Genetic Technologies Corporation (AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today reported positive three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP).
UF Neuroscience Students Lead Creation of New Mouse Model for Alzheimer’s Research
A research team led by University of Florida neuroscience graduate students has devised a new mouse model to study the protein tau, which can abnormally accumulate inside neurons and is associated with Alzheimer’s disease and related dementias.
UF First Among US Public Universities in Tech Transfer for Economic Return
The University of Florida ranks first among public universities and second nationwide in a new report that evaluates which U.S. universities are best at moving new discoveries from the lab and into the real world through research commercialization and STEM graduates.
UF Study: Post-COVID Mortality Risk May Be Caused by Effects of High Inflammation During Illness
A University of Florida study sheds new light on the reason people who recover from a bout of severe COVID-19 are still at increased risk for death in the year after their recovery. The culprit may be high levels of inflammation during the initial illness.
Cannabix Technologies Correlates THC in Breath and Blood Using Proprietary Sample Collection and Analysis Hardware in Experimental Study
UF startup Cannabix Technologies Inc. (the “Company or Cannabix”) developer of marijuana breathalyzer devices for law enforcement and the workplace reports it has successfully tested a supplemental version of its FAIMS technology for detection of ∆9-tetrahydrocannabinol (“THC”) and related analytes in human breath in an independent experimental study.
